In one paragraphArticle in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
31 authors.
Eric M JurgensAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-8280-2581 Sneha MitraComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-7718-8721 Kevin HerreraCenter for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0009-0001-2542-6388 David NemirovskyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0009-0007-6971-1408 Brenden BreadyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0009-0002-7166-9935 Andriy DerkachDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-2178-8493 Kinga HosszuImmune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-1190-1491 Devin McAvoyImmune Discovery and Modeling Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7807-6775 Ross S FirestoneMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-2945-9320 Sridevi RajeeveCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-3458-824X Alexander M LesokhinCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Neha KordeMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-5538-4318 Carlyn R TanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7922-2594 Hamza HashmiCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Hani HassounMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kylee MaclachlanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7873-4854 Urvi A ShahMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-8419-1091 Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-9045-6495 Maximilian MerzCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Francesco MauraMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sergio A GiraltAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-1944-5053 Gunjan L ShahAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-9977-0456 Heather J LandauAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-3152-1189 Michael ScordoAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ivan S KotchetkovDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-6202-9528 Bianca D SantomassoDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-9423-4059 Jae ParkCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Christina S LeslieComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-4571-5910 Saad Z UsmaniAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-5484-8731 Karlo PericaCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-3595-7596 Sham MailankodyCellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-2815-9561 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Nonimmune effector cell-associated neurotoxicity syndrome neurotoxicities (NINTs) are serious, atypical toxicities associated with ciltacabtagene autoleucel (cilta-cel), a US Food and Drug Administration chimeric antigen receptor T cell (CAR T cell) therapy approved for relapsed/refractory multiple myeloma (RRMM). Risk factors contributing to the development of NINTs are poorly understood. In a cohort of 109 patients with RRMM treated with cilta-cel, we identify predisposing risk factors and propose strategies to mitigate NINTs. We show that high-peak absolute lymphocyte count is a strong NINT predictor, which directly correlates with flow cytometry-based peripheral blood CAR T cell quantitation. The observed CAR lymphocytosis was polyclonal with a bias toward CD4
Indexed as
CD4-Positive T-LymphocytesImmunotherapy, AdoptiveMultiple MyelomaNeurotoxicity SyndromesReceptors, Chimeric AntigenCell ProliferationFemaleHumansLymphocytosisMaleMiddle AgedReceptors, Antigen, T-CellRisk FactorsReceptors, Antigen, T-CellReceptors, Chimeric Antigen
What OpenQuestion holds
Textmetadata
Read underepoch 390